CA2255842C - Rosacea treating agent - Google Patents
Rosacea treating agent Download PDFInfo
- Publication number
- CA2255842C CA2255842C CA002255842A CA2255842A CA2255842C CA 2255842 C CA2255842 C CA 2255842C CA 002255842 A CA002255842 A CA 002255842A CA 2255842 A CA2255842 A CA 2255842A CA 2255842 C CA2255842 C CA 2255842C
- Authority
- CA
- Canada
- Prior art keywords
- rosacea
- treating agent
- acid
- formula
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A rosacea treating agent is provided, which is effective even on intractable rosacea which cannot be cured completely by antibiotics such as minocycline, has low toxicity, causes little side effect, and is of long duration. The rosacea treating agent of the present invention comprises, as an active ingredient, at least one selected from the group consisting of benzoheterocyclic derivatives represented by the following formula (1): <IMG> wherein R is a lower alkyl group; and X is a halogen atom, and salts thereof. -23-
Description
- SPECIFICATION
ROSACEA TREATING AGENT
Technical Field The present invention relates to a treating agent for rosacea.
Backgrround Art Rosacea is, while rare among colored races, common among races with a light-colored skin, especially white races, and many cases occur among them. It is divided according to the symptoms into the first degree (telangiectatic rosacea on the forehead, cheeks, dorsum nasi), the second degree (acne rosacea, coexistence of follicular papules and pustules), and the third degree (rhinophyma, dark red tumor and dilated pore on apex nasi) . It starts with facial flush (redness) and eventually involves serious impairment of appearance, developing papules, pustules, rhinophyma, and tumor on apex nasi. It is also accompanied by seborrhea or enhancement of feeling of heat on the face due to emotional stress or change of environmental temperature.
Thus, these symptoms give a patient mental and physical suffering.
For the time being, the real cause of rosacea is unknown (Hifuka Chiryo Handbook, pp. 380-381, Nanzando (1987) and Gerd Plewing, Albert M. Kligman, ACNE arid ROSACEA, 2nd, Completely Revised and Enlarged Edition, pp. 431-454, Springer-Verlag (1993)). Rosacea is apt to be confused with acne, what is called pimple, classificationally. Rosacea, which can coexist with acne, essentially differs from acne. It is characterized by facial flush due to vascularization and proceeds with acne rosacea and tumor on apex nasi. A
digestive disease, hypertension, Demodex folliculon~, emotional stress, hereditary predisposition, etc. have been pointed out as a conceivable cause of rosacea, which has not been ascertained yet.
Therefore, there is no drug established as a remedy for rosacea, and the only method available now is symptomatic treatment, such as administration of minocycline or tetracycline antibiotics for the treatment of delayed skin diseases, use of metronidazole (anthelmintic), removal of mental stress, dietetic treatment, and supplemental concomitant use of vitamin BZ or B6.
Accordingly, it has been keenly demanded to study and develop more useful treating agents for rosacea.
ROSACEA TREATING AGENT
Technical Field The present invention relates to a treating agent for rosacea.
Backgrround Art Rosacea is, while rare among colored races, common among races with a light-colored skin, especially white races, and many cases occur among them. It is divided according to the symptoms into the first degree (telangiectatic rosacea on the forehead, cheeks, dorsum nasi), the second degree (acne rosacea, coexistence of follicular papules and pustules), and the third degree (rhinophyma, dark red tumor and dilated pore on apex nasi) . It starts with facial flush (redness) and eventually involves serious impairment of appearance, developing papules, pustules, rhinophyma, and tumor on apex nasi. It is also accompanied by seborrhea or enhancement of feeling of heat on the face due to emotional stress or change of environmental temperature.
Thus, these symptoms give a patient mental and physical suffering.
For the time being, the real cause of rosacea is unknown (Hifuka Chiryo Handbook, pp. 380-381, Nanzando (1987) and Gerd Plewing, Albert M. Kligman, ACNE arid ROSACEA, 2nd, Completely Revised and Enlarged Edition, pp. 431-454, Springer-Verlag (1993)). Rosacea is apt to be confused with acne, what is called pimple, classificationally. Rosacea, which can coexist with acne, essentially differs from acne. It is characterized by facial flush due to vascularization and proceeds with acne rosacea and tumor on apex nasi. A
digestive disease, hypertension, Demodex folliculon~, emotional stress, hereditary predisposition, etc. have been pointed out as a conceivable cause of rosacea, which has not been ascertained yet.
Therefore, there is no drug established as a remedy for rosacea, and the only method available now is symptomatic treatment, such as administration of minocycline or tetracycline antibiotics for the treatment of delayed skin diseases, use of metronidazole (anthelmintic), removal of mental stress, dietetic treatment, and supplemental concomitant use of vitamin BZ or B6.
Accordingly, it has been keenly demanded to study and develop more useful treating agents for rosacea.
An object of the present invention is to provide a useful rosacea treating agent.
Disclosure of the Invention The inventor of the present invention has conducted extensive study to develop a rosacea treating agent in the light of the above circumstances, and found as a result that at least one compound selected from the group consisting of benzoheterocyclic derivatives represented by the following formula (1):
O
X / COOH
N \ I NJ (1) HO
R
wherein R represents a lower alkyl group; and X
represents a halogen atom, and salts thereof is suitable as an active ingredient of a rosacea treating agent. The present invention has been completed based on this finding.
That is, the present invention relates to a rosacea treating agent comprising at least one selected from the group consisting of the above benzoheterocyclic derivatives represented by formula (1) and salts thereof as an active ingredient; use of at least one selected from the above compounds for preparing a rosacea treating agent; and a method for treating rosacea comprising using at least one selected from the above compounds.
The benzoheterocyclic derivatives represented by formula (1) or salts thereof are known from, e.g., Japanese Patent Publication No. 41127/89, which teaches details of a method for preparing these compounds and usefulness of the compounds as antimicrobial agents.
However, it is unpredictable even for one skilled in the art whether or not these benzoheterocyclic derivatives and their salts are effective for treating rosacea that has been considered baffling and difficult to cure.
The rosacea treating agent according to the present invention is effective even for treating intractable rosacea on which conventional antibiotics such as minocycline do not work, healing rosacea active papules, active pustules, erythema, and active efflorescence, and suppressing telangiectasia. It has low toxicity, causing little side effect, and is of long duration.
Disclosure of the Invention The inventor of the present invention has conducted extensive study to develop a rosacea treating agent in the light of the above circumstances, and found as a result that at least one compound selected from the group consisting of benzoheterocyclic derivatives represented by the following formula (1):
O
X / COOH
N \ I NJ (1) HO
R
wherein R represents a lower alkyl group; and X
represents a halogen atom, and salts thereof is suitable as an active ingredient of a rosacea treating agent. The present invention has been completed based on this finding.
That is, the present invention relates to a rosacea treating agent comprising at least one selected from the group consisting of the above benzoheterocyclic derivatives represented by formula (1) and salts thereof as an active ingredient; use of at least one selected from the above compounds for preparing a rosacea treating agent; and a method for treating rosacea comprising using at least one selected from the above compounds.
The benzoheterocyclic derivatives represented by formula (1) or salts thereof are known from, e.g., Japanese Patent Publication No. 41127/89, which teaches details of a method for preparing these compounds and usefulness of the compounds as antimicrobial agents.
However, it is unpredictable even for one skilled in the art whether or not these benzoheterocyclic derivatives and their salts are effective for treating rosacea that has been considered baffling and difficult to cure.
The rosacea treating agent according to the present invention is effective even for treating intractable rosacea on which conventional antibiotics such as minocycline do not work, healing rosacea active papules, active pustules, erythema, and active efflorescence, and suppressing telangiectasia. It has low toxicity, causing little side effect, and is of long duration.
In another aspect, the present invention provides a rosacea treating composition comprising a benzoheterocyclic compound represented by the following formula (1):
X ~aH
(1) HO
rt wherein R represents an alkyl group having 1 to 6 carbon atoms; and X represents a halogen atom, or a salt thereof, and a pharmaceutically acceptable carrier.
In another aspect, the present invention provides use of a benzoheterocyclic compound represented by formula (1) or a salt thereof for preparing a rosacea treating composition.
In another aspect, the present invention provides use of the rosacea treating composition of the present invention for treating rosacea.
- 4a -Hest F~abodiments for Carrving~ Out the Invention The rosacea treating agent according to the present invention comprises at least one selected from the group consisting of the above benzoheterocyclic derivatives represented by formula (1) and salts thereof as an active ingredient.
In formula (1), the lower alkyl group represented by R includes straight-chain or branched alkyl groups having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl and hexyl groups. The halogen atom represented by X includes a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
Of the compounds represented by formula (1) , (~) -9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]-quinolizine-2-carboxylic acid is particularly preferred.
The compound represented by formula (1) can be easily converted into acid-addition salts thereof by the reaction with a pharmaceutically acceptable acid. The acid includes inorganic acids, such as hydrochloric acid, sulfuric acid, phosphoric acid, and hydrobromic acid;
and organic acids, such as oxalic acid, malefic acid, fumaric acid, malic acid, tartaric acid, citric acid, and benzoic acid. The compounds represented by formula (1) can easily be converted into salts thereof by the reaction with a pharmaceutically acceptable alkaline compound. The alkaline compound includes sodium hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, and potassium hydrogencarbonate.
The compound represented by formula (1) of the present invention and salts thereof can be easily isolated and purified by ordinary separation means, such as solvent extraction, dilution, recrystallization, column chromatography, preparative thin layer chromatography, and the like.
In using the compound represented by formula (1) and salts thereof as a rosacea treating agent, they are generally compounded into pharmaceutical compositions together with pharmaceutically acceptable carriers which are commonly employed in preparing drugs of dose form conformable to the method of administration. Suitable carriers which can be used include diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, etc.
The rosacea treating agent can have various dosage forms in accordance with the purpose of the therapy. Typical dosage forms include tablets, pills, powders, liquid preparations, suspensions, emulsions, granules, capsules, suppositories, injectable preparations (solutions, suspensions, etc.); sprays, such as inhalations and aerosol for external use;
liquids for topical application, lotions, .gels, oily ointments; emulsified ointments, such as O/W hydrophilic ointments and W/O water-absorbent ointments; water-soluble ointments, creams, liniments, cataplasms, pastes, plasters, external preparation such as emulsions, and sheets.
If the pharmaceutical composition is formulated into tablets, a wide range of carriers known in the art can be used. Examples of suitable carriers include excipients such as lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, and silicic acid; binders such as water, ethanol, propanol, simple syrup, a glucose solution, a starch solution, a gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate, and polyvinylpyrrolidone;
disintegrants such as dried starch, sodium alginate, agar powder, laminaria powder, sodium hydrogencarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium laurylsulfate, glycerol monostearate, starch, and lactose; disintegration inhibitors such as white sugar, stearin, cacao butter, and hydrogenated oils; absorption promoters such as quaternary ammonium bases and sodium laurylsulfate; humectants such as glycerol and starch; adsorbents such as starch, lactose, kaolin, bentonite, and colloidal silicic. acid; and lubricants such as purified talc, stearic acid salts, boric acid powder, and polyethylene glycol. The tablets, if desired, can be coated tablets having a general coat, such as sugar-coated tablets, gelatin-coated tablets, enteric coated tablets, film-coated tablets, double-layered coated tablets, or multilayered coated tablets.
In formulating into pills, carriers well known in the art can be used widely. Examples of suitable carriers are excipients such as glucose, lactose, starch, cacao butter, hardened vegetable oils, kaolin, and talc;
binders such as gum arabic powder, tragacanth powder, gelatin, and ethanol; and disintegrants such as laminaria and agar. In formulating into suppositories, carriers well known in the art can be used widely.
Examples are polyethylene glycol, cacao butter, higher alcohols, higher alcohol esters, gelatin, and semisynthetic glycerides. Capsules are generally prepared by mixing the active ingredient with the above-enumerated various carriers and packing the mixture into hard gelatin capsules or soft capsules. Solutions, emulsions or suspensions as injectable preparations are preferably sterilized and made isotonic with blood. In _ g _ preparing these preparations, all diluents customarily used in the art, such as water, ethanol, Macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, and polyoxyethylene sorbitan fatty acid esters, can be used. Sodium chloride, glucose or glycerol may be incorporated into the injectable preparation in an amount sufficient for making it isotonic. The injectable preparations can contain general dissolution aid, buffers, pain-alleviating agents, and the like. The pharmaceutical compositions can contain coloring agents, preservatives, perfumes, flavors, sweeteners, and other drugs. In formulating the pharmaceutical composition into pastes, creams or gels , a wide variety of diluents known in the art can be used. Examples are white petrolatum, paraffin, glycerol, cellulose derivatives, polyethylene glycol, silicone, and bentonite.
Bases which can be used for an external preparation comprise an oily base or a mixture of two or more oily bases or a water-soluble base or a mixture of two or more water-soluble bases. Examples of suitable bases are fats and oils such as peanut oil, sesame oil, soybean oil , safflower oil , avocado oil , sunflower oil , corn oil, rape seed oil, cotton seed oil, castor oil, camellia oil, palm oil, olive oil, poppy seed oil, _ g _ coconut oil, beef tallow, lard, and lanolin; modified fats and oils prepared by subjecting the above-described fats and oils to a chemical change such as hydrogenation; mineral oils such as vaseline, paraffin, silicone oil, and squalane; higher fatty acid esters, higher fatty acid alcohols and waxes such as isopropyl myristate, N-butyl myristate, isopropyl linolate, propyl ricinoleate, isopropyl ricinoleate, isobutyl ricinoleate, heptyl ricinoleate, diethyl sebacate, diisopropyl adipate, cetyl alcohol, stearyl alcohol, white beeswax, cetaceum, Japan wax, lanolin, carnauba wax, and shellac wax; higher fatty acids such as stearic acid, oleic acid and palmitic acid; mono-, di- and triglyceride mixtures of saturated or unsaturated fatty acids having 12 to 18 carbon atoms; polyhydric alcohols such as ethylene glycol, polyethylene glycol, propylene glycol, polypropylene glycol, glycerol, butyl alcohol, pentaerythritol, sorbitol, and mannitol; gum such as gum arabic, gum benzoin, guaiac resin, ad gum tragacanth;
naturally occurring water-soluble polymers such as gelatin, starch, casein, dextrin, pectin, sodium pectin, sodium alginate, methyl cellulose, ethyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, nitrocellulose, and crystalline cellulose; synthetic water-soluble polymers such as polyvinyl alcohol, polyvinyl methyl ether, polyvinylpyrrolidone, sodium polyacrylate, carboxyvinyl polymers, and polyethyleneimine; nonionic, anionic, amphoteric or cation surfactants; ethanol, isopropyl alcohol, and the like.
These external preparations, if desired, can contain various known bases such as excipients, binders, lubricants, and disintegrants. If desired, they can also contain oily materials such as various fats and oils, waxes, hydrocarbons, fatty acids, higher alcohols, ester oils and metallic soaps, animal or vegetable extracts, pharmaceutically effective components such as vitamins, hormones, and amino acids, surfactants, coloring matters, dyes, pigments, perfumes, antiseptics, antimicrobial agents, humectants, thickeners, antioxidants, sequestering agents, ultraviolet absorbers, ultraviolet scattering agents, or any other known components and additives as long as the effects of the present invention are not impaired.
The amount of the active compound to be incorporated into the rosacea treating agent of the present invention is not particularly limited and can vary over a wide range. A suitable effective amount is usually from about 1 to 705 by weight based on the total composition.
There is no particular restriction on the manner of using the rosacea treating agent, and the treating agent can be administered by routes suitable for the particular forms of the preparation, the age, sex or other conditions of patients, the symptoms, and the like.
For example, the tablets, pills, liquid preparations, suspensions, emulsions, granules and capsules are orally administered. The injectable preparations are intravenously administered either alone or together with ordinary auxiliary agents such as glucose and amino acids. As required, the injectable preparations can be singly administered intramuscularly, intracutaneously, subcutaneously or intraperitoneally. The suppositories are administered intrarectally, and the external preparations are applied onto the skin.
The dosage of the rosacea treating agent of the present invention is appropriately selected according to the administration route, the age, sex or other conditions of a patient, the symptoms, etc. Usually, a preferred dose of the active compound is about 0.2 to 100 mg/kg body weight in 3 or 4 divided doses per day.
An external preparation is applied once or twice a day at a dose of about 10 mg of the active compound per day.
Examples The present invention will now be illustrated in greater detail by way of formulation examples and pharmacological test example.
Formulation Example 1 Compound of formula (I) 200 mg Glucose 250 mg Injectable distilled water appropriate amount Total 5 ml The compound of formula (1) and glucose were dissolved in injectable distilled water, and the solution was put into a 5 ml-volume ampule. After substitution with nitrogen, the solution was sterilized by autoclaving at 121°C for 15 minutes to obtain an injection having the above composition.
Formulation Example 2 Compound of formula (1) 100 g Avicel (trade name, a product of 40 g Asahi Chemical Industry Co., htd.) Corn starch 30 g Magnesium stearate 2 g Hydroxypropylmethyl cellulose 10 g * Trade-mar k Polyethylene glycol-6000 3 g Castor oil 40 g Ethanol . 40 g The compound of the invention, Avicel, corn starch, and magnesium stearate were mixed, ground, and punched using a pestle of sugar coating R=10 mm. The resulting tablets were coated with a film coating agent comprising hydroxypropyl methyl cellulose, polyethylene glycol-6000, castor oil and ethanol to obtain film-coated tablets.
Formulation Exams 3 (~)-9-Fluoro-6,7-dihydro-8-(4- 2 g hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid Purified lanolin 5 g White beeswax 5 g White petrolatum 88 g Total 100 g White beeswax was liquefied by heating, and the compound of the invention, purified lanolin and white petrolatum were added thereto. After once heated to liquefy, the mixture was stirred till it began to solidify to obtain an ointment of the above composition.
Formulation Example 4 Cream:
(~)-9-Fluoro-6,7-dihydro-8-(4- 1.0 g hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,SH-benzo[i,j]quinolizine-2-carboxylic acid White petrolatum 10.0 g Light liquid paraffin 9.0 g Stearyl alcohol 4.0 g Polyoxyethylene cetyl ether 3.0 g Concentrated glycerin 10.0 g Purified water and the like appropriate amount Total 100.0 g Formulation Component I:
White petrolatum 10.0 g Light liquid paraffin 9.0 g Stearyl alcohol 4.0 g Cetanol 4.0 g Polyoxyethylene cetyl ether 3.0 g Component II:
(~) -9-Fluoro-6, 7-dihydro-8- (4- 1. 0 g hydroxy-1-piperidyl)-5-methyl-1-oxo- .
1H,5H-benzo[i,j]quinolizine-2-carboxylic acid Glycerin 10.0 g Di ( ~i-hydroxyethyl ) amine 0 . 1 g Purified water 58.9 g An external preparation in cream form was obtained in the same manner as in Formulation Example 4.
Formulation Example 6 Ointment:
White petrolatum 73.54 g Light liquid paraffin 10.0 g Cetanol 5.0 g Cholesterol 4.0 g ()-9-Fluoro-6,7-dihydro-8-(4- 1.0 g hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid Sodium hydroxide 0.112 g Propylene glycol 5.0 g Di ((3-hydroxyethyl) amine 0 . g Disodium edetate 0.1 g Purified water 1.048 g Formulation Component I:
White petrolatum 6.5 g Light liquid paraffin 6.0 g Stearyl alcohol 2.5 g Cetanol 2.5 g Polyoxyethylene cetyl ether 2.0 g Component II:
()-9-Fluoro-6,7-dihydro-8-(4- 1.0 g hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid Sodium hydroxide 0.112 g Di ((3-hydroxyethyl) amine 0 . 36 g Purified water 79.028 g Component I was heated to about 80C to melt.
Separately, component II was mixed, dissolved, and heated to about 80C. The heated components I and II
were mixed and cooled to obtain an external preparation in emulsion form.
Formulation Exaa~le 8 Lotion:
()-9-Fluoro-6,7-dihydro-8-(4- . 1.0 g hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid Isopropyl alcohol 62.4 g Propylene glycol 2.5 g Tri ((3-hydroxyethyl) amine 0 . g Sodium hydroxide 0.2 g Purified water appropri ate amount Total 1000 ml A cream prepared in accordance with Formulation Example 4, which contained 1~ of (~)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]-quinolizine-2-carboxylic acid, was applied to the face of 13 rosacea patients suffering from facial flush and 15 or more active pustules or papules on their face twice a day. Of the 13 cases, 11 had received medical treatment With minocycline (6 cases), metronidazole (5 cases), oxytetracycline (2 cases), erythromycin (2 cases), tetracycline (1 case), benzoyl peroxide (1 case) , zinc acetate (1 case) , doxycycline (1 case) , fluocinonide (1 case) , nystatin (1 case) or white petrolatum (1 case) .
After 12 weeks from the start of the treatment with the cream, the physician in charge judged the degree of overall improvement in the patients on cream therapy based on 5 scales of cure, remarkable improvement, improvement, no change, and aggravation.
As a result, of 13 cases 2 cases (15.4 of the total) were judged as cure and 9 cases (69.2 of the total) as remarkable improvement, proving that the rate of improvement reached 84.6. There were only 2 cases (15.4 of the total) judged as no change.
It is seen from these results that the rosacea treating agent according to the present invention brings about improvement on rosacea symptoms, exhibiting effectiveness even on those patients who had not been cured completely by previous therapy.
Industrial Agnlicability The benzoheterocyclic derivatives of formula (1) and salts thereof are useful as a rosacea treating agent that is effective even on baffling and intractable rosacea which cannot be cured completely by conventional antibiotics such as minocycline, has low toxicity, causes little side effect, and is of long duration.
X ~aH
(1) HO
rt wherein R represents an alkyl group having 1 to 6 carbon atoms; and X represents a halogen atom, or a salt thereof, and a pharmaceutically acceptable carrier.
In another aspect, the present invention provides use of a benzoheterocyclic compound represented by formula (1) or a salt thereof for preparing a rosacea treating composition.
In another aspect, the present invention provides use of the rosacea treating composition of the present invention for treating rosacea.
- 4a -Hest F~abodiments for Carrving~ Out the Invention The rosacea treating agent according to the present invention comprises at least one selected from the group consisting of the above benzoheterocyclic derivatives represented by formula (1) and salts thereof as an active ingredient.
In formula (1), the lower alkyl group represented by R includes straight-chain or branched alkyl groups having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl and hexyl groups. The halogen atom represented by X includes a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
Of the compounds represented by formula (1) , (~) -9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]-quinolizine-2-carboxylic acid is particularly preferred.
The compound represented by formula (1) can be easily converted into acid-addition salts thereof by the reaction with a pharmaceutically acceptable acid. The acid includes inorganic acids, such as hydrochloric acid, sulfuric acid, phosphoric acid, and hydrobromic acid;
and organic acids, such as oxalic acid, malefic acid, fumaric acid, malic acid, tartaric acid, citric acid, and benzoic acid. The compounds represented by formula (1) can easily be converted into salts thereof by the reaction with a pharmaceutically acceptable alkaline compound. The alkaline compound includes sodium hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, and potassium hydrogencarbonate.
The compound represented by formula (1) of the present invention and salts thereof can be easily isolated and purified by ordinary separation means, such as solvent extraction, dilution, recrystallization, column chromatography, preparative thin layer chromatography, and the like.
In using the compound represented by formula (1) and salts thereof as a rosacea treating agent, they are generally compounded into pharmaceutical compositions together with pharmaceutically acceptable carriers which are commonly employed in preparing drugs of dose form conformable to the method of administration. Suitable carriers which can be used include diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, etc.
The rosacea treating agent can have various dosage forms in accordance with the purpose of the therapy. Typical dosage forms include tablets, pills, powders, liquid preparations, suspensions, emulsions, granules, capsules, suppositories, injectable preparations (solutions, suspensions, etc.); sprays, such as inhalations and aerosol for external use;
liquids for topical application, lotions, .gels, oily ointments; emulsified ointments, such as O/W hydrophilic ointments and W/O water-absorbent ointments; water-soluble ointments, creams, liniments, cataplasms, pastes, plasters, external preparation such as emulsions, and sheets.
If the pharmaceutical composition is formulated into tablets, a wide range of carriers known in the art can be used. Examples of suitable carriers include excipients such as lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, and silicic acid; binders such as water, ethanol, propanol, simple syrup, a glucose solution, a starch solution, a gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate, and polyvinylpyrrolidone;
disintegrants such as dried starch, sodium alginate, agar powder, laminaria powder, sodium hydrogencarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium laurylsulfate, glycerol monostearate, starch, and lactose; disintegration inhibitors such as white sugar, stearin, cacao butter, and hydrogenated oils; absorption promoters such as quaternary ammonium bases and sodium laurylsulfate; humectants such as glycerol and starch; adsorbents such as starch, lactose, kaolin, bentonite, and colloidal silicic. acid; and lubricants such as purified talc, stearic acid salts, boric acid powder, and polyethylene glycol. The tablets, if desired, can be coated tablets having a general coat, such as sugar-coated tablets, gelatin-coated tablets, enteric coated tablets, film-coated tablets, double-layered coated tablets, or multilayered coated tablets.
In formulating into pills, carriers well known in the art can be used widely. Examples of suitable carriers are excipients such as glucose, lactose, starch, cacao butter, hardened vegetable oils, kaolin, and talc;
binders such as gum arabic powder, tragacanth powder, gelatin, and ethanol; and disintegrants such as laminaria and agar. In formulating into suppositories, carriers well known in the art can be used widely.
Examples are polyethylene glycol, cacao butter, higher alcohols, higher alcohol esters, gelatin, and semisynthetic glycerides. Capsules are generally prepared by mixing the active ingredient with the above-enumerated various carriers and packing the mixture into hard gelatin capsules or soft capsules. Solutions, emulsions or suspensions as injectable preparations are preferably sterilized and made isotonic with blood. In _ g _ preparing these preparations, all diluents customarily used in the art, such as water, ethanol, Macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, and polyoxyethylene sorbitan fatty acid esters, can be used. Sodium chloride, glucose or glycerol may be incorporated into the injectable preparation in an amount sufficient for making it isotonic. The injectable preparations can contain general dissolution aid, buffers, pain-alleviating agents, and the like. The pharmaceutical compositions can contain coloring agents, preservatives, perfumes, flavors, sweeteners, and other drugs. In formulating the pharmaceutical composition into pastes, creams or gels , a wide variety of diluents known in the art can be used. Examples are white petrolatum, paraffin, glycerol, cellulose derivatives, polyethylene glycol, silicone, and bentonite.
Bases which can be used for an external preparation comprise an oily base or a mixture of two or more oily bases or a water-soluble base or a mixture of two or more water-soluble bases. Examples of suitable bases are fats and oils such as peanut oil, sesame oil, soybean oil , safflower oil , avocado oil , sunflower oil , corn oil, rape seed oil, cotton seed oil, castor oil, camellia oil, palm oil, olive oil, poppy seed oil, _ g _ coconut oil, beef tallow, lard, and lanolin; modified fats and oils prepared by subjecting the above-described fats and oils to a chemical change such as hydrogenation; mineral oils such as vaseline, paraffin, silicone oil, and squalane; higher fatty acid esters, higher fatty acid alcohols and waxes such as isopropyl myristate, N-butyl myristate, isopropyl linolate, propyl ricinoleate, isopropyl ricinoleate, isobutyl ricinoleate, heptyl ricinoleate, diethyl sebacate, diisopropyl adipate, cetyl alcohol, stearyl alcohol, white beeswax, cetaceum, Japan wax, lanolin, carnauba wax, and shellac wax; higher fatty acids such as stearic acid, oleic acid and palmitic acid; mono-, di- and triglyceride mixtures of saturated or unsaturated fatty acids having 12 to 18 carbon atoms; polyhydric alcohols such as ethylene glycol, polyethylene glycol, propylene glycol, polypropylene glycol, glycerol, butyl alcohol, pentaerythritol, sorbitol, and mannitol; gum such as gum arabic, gum benzoin, guaiac resin, ad gum tragacanth;
naturally occurring water-soluble polymers such as gelatin, starch, casein, dextrin, pectin, sodium pectin, sodium alginate, methyl cellulose, ethyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, nitrocellulose, and crystalline cellulose; synthetic water-soluble polymers such as polyvinyl alcohol, polyvinyl methyl ether, polyvinylpyrrolidone, sodium polyacrylate, carboxyvinyl polymers, and polyethyleneimine; nonionic, anionic, amphoteric or cation surfactants; ethanol, isopropyl alcohol, and the like.
These external preparations, if desired, can contain various known bases such as excipients, binders, lubricants, and disintegrants. If desired, they can also contain oily materials such as various fats and oils, waxes, hydrocarbons, fatty acids, higher alcohols, ester oils and metallic soaps, animal or vegetable extracts, pharmaceutically effective components such as vitamins, hormones, and amino acids, surfactants, coloring matters, dyes, pigments, perfumes, antiseptics, antimicrobial agents, humectants, thickeners, antioxidants, sequestering agents, ultraviolet absorbers, ultraviolet scattering agents, or any other known components and additives as long as the effects of the present invention are not impaired.
The amount of the active compound to be incorporated into the rosacea treating agent of the present invention is not particularly limited and can vary over a wide range. A suitable effective amount is usually from about 1 to 705 by weight based on the total composition.
There is no particular restriction on the manner of using the rosacea treating agent, and the treating agent can be administered by routes suitable for the particular forms of the preparation, the age, sex or other conditions of patients, the symptoms, and the like.
For example, the tablets, pills, liquid preparations, suspensions, emulsions, granules and capsules are orally administered. The injectable preparations are intravenously administered either alone or together with ordinary auxiliary agents such as glucose and amino acids. As required, the injectable preparations can be singly administered intramuscularly, intracutaneously, subcutaneously or intraperitoneally. The suppositories are administered intrarectally, and the external preparations are applied onto the skin.
The dosage of the rosacea treating agent of the present invention is appropriately selected according to the administration route, the age, sex or other conditions of a patient, the symptoms, etc. Usually, a preferred dose of the active compound is about 0.2 to 100 mg/kg body weight in 3 or 4 divided doses per day.
An external preparation is applied once or twice a day at a dose of about 10 mg of the active compound per day.
Examples The present invention will now be illustrated in greater detail by way of formulation examples and pharmacological test example.
Formulation Example 1 Compound of formula (I) 200 mg Glucose 250 mg Injectable distilled water appropriate amount Total 5 ml The compound of formula (1) and glucose were dissolved in injectable distilled water, and the solution was put into a 5 ml-volume ampule. After substitution with nitrogen, the solution was sterilized by autoclaving at 121°C for 15 minutes to obtain an injection having the above composition.
Formulation Example 2 Compound of formula (1) 100 g Avicel (trade name, a product of 40 g Asahi Chemical Industry Co., htd.) Corn starch 30 g Magnesium stearate 2 g Hydroxypropylmethyl cellulose 10 g * Trade-mar k Polyethylene glycol-6000 3 g Castor oil 40 g Ethanol . 40 g The compound of the invention, Avicel, corn starch, and magnesium stearate were mixed, ground, and punched using a pestle of sugar coating R=10 mm. The resulting tablets were coated with a film coating agent comprising hydroxypropyl methyl cellulose, polyethylene glycol-6000, castor oil and ethanol to obtain film-coated tablets.
Formulation Exams 3 (~)-9-Fluoro-6,7-dihydro-8-(4- 2 g hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid Purified lanolin 5 g White beeswax 5 g White petrolatum 88 g Total 100 g White beeswax was liquefied by heating, and the compound of the invention, purified lanolin and white petrolatum were added thereto. After once heated to liquefy, the mixture was stirred till it began to solidify to obtain an ointment of the above composition.
Formulation Example 4 Cream:
(~)-9-Fluoro-6,7-dihydro-8-(4- 1.0 g hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,SH-benzo[i,j]quinolizine-2-carboxylic acid White petrolatum 10.0 g Light liquid paraffin 9.0 g Stearyl alcohol 4.0 g Polyoxyethylene cetyl ether 3.0 g Concentrated glycerin 10.0 g Purified water and the like appropriate amount Total 100.0 g Formulation Component I:
White petrolatum 10.0 g Light liquid paraffin 9.0 g Stearyl alcohol 4.0 g Cetanol 4.0 g Polyoxyethylene cetyl ether 3.0 g Component II:
(~) -9-Fluoro-6, 7-dihydro-8- (4- 1. 0 g hydroxy-1-piperidyl)-5-methyl-1-oxo- .
1H,5H-benzo[i,j]quinolizine-2-carboxylic acid Glycerin 10.0 g Di ( ~i-hydroxyethyl ) amine 0 . 1 g Purified water 58.9 g An external preparation in cream form was obtained in the same manner as in Formulation Example 4.
Formulation Example 6 Ointment:
White petrolatum 73.54 g Light liquid paraffin 10.0 g Cetanol 5.0 g Cholesterol 4.0 g ()-9-Fluoro-6,7-dihydro-8-(4- 1.0 g hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid Sodium hydroxide 0.112 g Propylene glycol 5.0 g Di ((3-hydroxyethyl) amine 0 . g Disodium edetate 0.1 g Purified water 1.048 g Formulation Component I:
White petrolatum 6.5 g Light liquid paraffin 6.0 g Stearyl alcohol 2.5 g Cetanol 2.5 g Polyoxyethylene cetyl ether 2.0 g Component II:
()-9-Fluoro-6,7-dihydro-8-(4- 1.0 g hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid Sodium hydroxide 0.112 g Di ((3-hydroxyethyl) amine 0 . 36 g Purified water 79.028 g Component I was heated to about 80C to melt.
Separately, component II was mixed, dissolved, and heated to about 80C. The heated components I and II
were mixed and cooled to obtain an external preparation in emulsion form.
Formulation Exaa~le 8 Lotion:
()-9-Fluoro-6,7-dihydro-8-(4- . 1.0 g hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid Isopropyl alcohol 62.4 g Propylene glycol 2.5 g Tri ((3-hydroxyethyl) amine 0 . g Sodium hydroxide 0.2 g Purified water appropri ate amount Total 1000 ml A cream prepared in accordance with Formulation Example 4, which contained 1~ of (~)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]-quinolizine-2-carboxylic acid, was applied to the face of 13 rosacea patients suffering from facial flush and 15 or more active pustules or papules on their face twice a day. Of the 13 cases, 11 had received medical treatment With minocycline (6 cases), metronidazole (5 cases), oxytetracycline (2 cases), erythromycin (2 cases), tetracycline (1 case), benzoyl peroxide (1 case) , zinc acetate (1 case) , doxycycline (1 case) , fluocinonide (1 case) , nystatin (1 case) or white petrolatum (1 case) .
After 12 weeks from the start of the treatment with the cream, the physician in charge judged the degree of overall improvement in the patients on cream therapy based on 5 scales of cure, remarkable improvement, improvement, no change, and aggravation.
As a result, of 13 cases 2 cases (15.4 of the total) were judged as cure and 9 cases (69.2 of the total) as remarkable improvement, proving that the rate of improvement reached 84.6. There were only 2 cases (15.4 of the total) judged as no change.
It is seen from these results that the rosacea treating agent according to the present invention brings about improvement on rosacea symptoms, exhibiting effectiveness even on those patients who had not been cured completely by previous therapy.
Industrial Agnlicability The benzoheterocyclic derivatives of formula (1) and salts thereof are useful as a rosacea treating agent that is effective even on baffling and intractable rosacea which cannot be cured completely by conventional antibiotics such as minocycline, has low toxicity, causes little side effect, and is of long duration.
Claims (4)
1. A rosacea treating composition comprising a benzoheterocyclic compound represented by the following formula (1):
wherein R represents an alkyl group having 1 to 6 carbon atoms; and X represents a halogen atom, or a salt thereof, and a pharmaceutically acceptable carrier.
wherein R represents an alkyl group having 1 to 6 carbon atoms; and X represents a halogen atom, or a salt thereof, and a pharmaceutically acceptable carrier.
2. The rosacea treating composition as defined in claim 1, wherein the benzoheterocyclic compound is (~)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]-quinolizine-2-carboxylic acid or a salt thereof.
3. Use of a benzoheterocyclic compound represented by formula (1):
wherein R represents an alkyl group having 1 to 6 carbon atoms; and X represents a halogen atom, or a salt thereof, for preparing a rosacea treating composition.
wherein R represents an alkyl group having 1 to 6 carbon atoms; and X represents a halogen atom, or a salt thereof, for preparing a rosacea treating composition.
4. Use of the rosacea treating composition as defined in any one of claims 1 to 2 for treating rosacea.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12453196 | 1996-05-20 | ||
| JP8-124531 | 1996-05-20 | ||
| PCT/JP1997/001667 WO1997044034A1 (en) | 1996-05-20 | 1997-05-19 | Remedy for rosacea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2255842A1 CA2255842A1 (en) | 1997-11-27 |
| CA2255842C true CA2255842C (en) | 2007-04-10 |
Family
ID=38007253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002255842A Expired - Fee Related CA2255842C (en) | 1996-05-20 | 1997-05-19 | Rosacea treating agent |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2255842C (en) |
-
1997
- 1997-05-19 CA CA002255842A patent/CA2255842C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2255842A1 (en) | 1997-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6136806A (en) | Remedy for rosacea | |
| EP2575816B1 (en) | Combination therapy for skin disorders | |
| US4933330A (en) | Benzoic acid derivatives and use thereof | |
| US6177471B1 (en) | Method for treating patients with acne by administering a CGMP-specific PDE inhibitor | |
| JPS62246515A (en) | Antipsoriatic containing tamoxiphen or pharmacologically acceptable salt of same | |
| CA2660939A1 (en) | Pharmaceutical compositions for the treatment of fungal infections | |
| JPH0753359A (en) | Lipoxygenase inhibitor | |
| JP2023184678A (en) | Compositions and methods for treating cutaneous fibrosis | |
| CA2255842C (en) | Rosacea treating agent | |
| US4352813A (en) | [(1-Benzyl-1H-indazol-3-yl)oxy] acetic acid salt with L. lysine | |
| US5902827A (en) | Method for treating patients with psoriasis by administering substituted sulfonyl indenyl acetic acids, esters and alcohols | |
| US4150141A (en) | Treatment for scabies | |
| EP1621191A1 (en) | Treatment of inflammatory diseases by RXR Antagonists | |
| JP4096127B2 (en) | Rosacea treatment | |
| EP0848610A1 (en) | Use of a carbostyril derivative for inhibiting carcinogenesis | |
| US3887706A (en) | N6-(3-Chlorobuten-2-yl)-adenosines as anti-inflammatory agents | |
| JP4447685B2 (en) | Dry skin disease treatment | |
| HU196122B (en) | Process for preparing pharmaceuticals comprising 9alpha, 11beta-dichlor-16alpha-methyl-21-(dicyclohexyl-methyloxy-carbonyloxy)-pregno-1,4-dien-3,20-dione | |
| DE60032114T2 (en) | METHOD OF TREATMENT OF ACNEEPATIENTS BY ADMINISTERING CYCLIC GMP PDE INHIBITORS | |
| JP3654939B2 (en) | Driver Jain treatment | |
| JP3701111B2 (en) | Antipruritic | |
| WO2023220768A1 (en) | Acne control formulations | |
| WO2023230418A1 (en) | Mutual prodrugs of cromoglicic acid | |
| JP2003002828A (en) | Preventing or therapeutic agent for inflammatory disease of mucosa of oral cavity, or the like | |
| JPH04275215A (en) | Anti-inflammatory and analgesic agent for external use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20170519 |